Is cardiovascular comorbidity the cause of elevated C-reactive protein in Covid-19 positive patients?

Authors

Keywords:

Covid-19, SARS‐CoV-2, C reactive protein, cardiovascular comorbidity

Abstract

Introduction: recent epidemiological studies in China have reported an increased risk for the patient with heart comorbidities in patients with the coronavirus 19. Objectives: to determine the degree of association between the reported cardiovascular morbidity and the elevation of C-reactive protein in patients positive for the coronavirus 19. Methods: a cross-sectional descriptive study was carried out on a sample of 52 patients diagnosed with coronavirus 19 and hospitalized in the “Celestino Hernández Robau” Hospital in Santa Clara city, Villa Clara, Cuba which was dedicated exclusively to the care of this type of patient during the pandemic. Two groups were formed based on the presence of cardiovascular comorbidity. Results: among the associated comorbidities, arterial hypertension predominated (32.7%), there were no significant differences between the proportion of individuals with a high or normal C-reactive protein, regardless of the group they were in (p=0.79). Conclusions: there was no important association between cardiovascular morbidity and C-reactive protein elevation in coronavirus-positive patients 19.

Downloads

Download data is not yet available.

Author Biography

Guillermo Alberto Pérez Fernández, Hospital Universitario “Celestino Hernández Robau”

Especialista de I Grado en Medicina General Integral. Especialista de I y II Grado en Cardiología. Doctor en Ciencias Médicas. Profesor Titular en la Universidad de Ciencias Médias de Villa Clara.

References

1. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol [Internet]. 2020 Mar [citado 4 May 2020];92(6):568-575. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25748. https://doi.org/10.1002/jmv.25748

2. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol [Internet]. 2020 Apr [citado 4 May 2020];92(4):418‐423. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25681

3. Cheng P, Zhu H, Witteles RM, Wu JC, Quertermous T, Wu SM, Rhee JW. Cardiovascular risks in patients with COVID-19: potential mechanisms and areas of uncertainty. Curr Cardiol Rep [Internet]. 2020 Apr [citado 4 May 2020];22(5):34. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189178/. https://doi.org/10.1007/s11886-020-01293-2

4. He XW, Lai JS, Cheng J, Wang MW, Liu YJ, Xiao ZC, et al. Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients. Zhonghua Xin Xue Guan Bing Za Zhi [Internet]. 2020 Mar [citado 4 May 2020];48(0):E011. Disponible en: https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwho-8400

5. Sierra R, Rello J, Bailén MA, Benítez E, Gordillo A, León C, et al. C-reactive protein used as an early indicator of infection in patients with systemic inflammatory response syndrome. Intensive Care Med [Internet]. 2004 Sep [citado 4 May 2020];30(11):2038-2045. Disponible en: https://link.springer.com/article/10.1007/s00134-004-2434-y

6. Batún Garrido JAJ, García Padrón OA, Salas Magaña M. Proteína C reactiva como marcador de riesgo cardiovascular en una cohorte de pacientes con artritis reumatoide. Rev Cubana Reumatol [Internet]. 2016 May-Ago [citado 4 May 2020];18(2):111-9. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1817-59962016000200003

7. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentraxins) and serum amyloid A protein. Adv Immunol [Internet]. 1983 Jan [citado 4 May 2020];34:141-212. Disponible en: https://www.sciencedirect.com/science/article/pii/S006527760860379X?via%3Dihub

8. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation [Internet]. 2003 Jan [citado 4 May 2020];107(3):363-9. Disponible en: https://www.ahajournals.org/doi/full/10.1161/01.cir.0000053730.47739.3c

9. Sakkinen P, Abbott RD, Curb JD, Rodriguez Bl, Yano K, Tracy RP. C-reactive protein and myocardial infarction. J Clin Epidemiol [Internet]. 2002 [citado 4 May 2020];55:445-51. Disponible en: https://pubmed.ncbi.nlm.nih.gov/12007546/. https://doi.org/10.1016/S0895-4356(01)00502-9

10. Jialal I, Devaraj S, Venugopal SK: C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension [Internet]. 2004 Jul [citado 4 May 2020];44(1):6-11. Disponible en: https://www.ahajournals.org/doi/full/10.1161/01.HYP.0000130484.20501.df

11. Fernández LM. Marcadores de inflamación en enfermedades cardiovasculares. Medicina & Laboratorio [Internet]. 2008 [citado 4 May 2020];14(11-12):547-56. Disponible en: https://www.medigraphic.com/pdfs/medlab/myl-2008/myl0811-12d.pdf

12. Palma E, González V, Grünholz D, Landaeta M, Mallea M, Pérez J, et al. Tormenta de citoquinas: reacción adversa inhabitual por rituximab. Caso clínico. Rev Med Chile [Internet]. 2017 Feb [citado 4 May 2020];145(2):260-3. Disponible en: https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872017000200015

13. Ballou SP, Kushner I. Laboratory evaluation of inflammation. In: Ruddy S, Harris ED, Sledge CB (Eds). Kelley’s Textbook of Rheumatology. Philadelphia, JB Saunders Company; 2001. p. 697-703.

14. Wilson PW, Nam BH, Pencina M, D’agostino RB, Benjamin EJ, O’donnell CJ.C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med [Internet]. 2005 Nov [citado 4 May 2020];165(21):2473-8.Disponible en: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/486823

Downloads

Published

2020-07-06

How to Cite

1.
Pérez Fernández GA. Is cardiovascular comorbidity the cause of elevated C-reactive protein in Covid-19 positive patients?. Acta Méd Centro [Internet]. 2020 Jul. 6 [cited 2025 Jul. 6];14(3):304-12. Available from: https://revactamedicacentro.sld.cu/index.php/amc/article/view/1294

Issue

Vol. 14 No. 3 (2020): July-September

Section

Original Articles

License

Authors who have publications with this journal agree to the following terms:

  1. Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
  2. Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
  3. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).